National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Ibrutinib (Imbruvica®) is indicated in the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

Rapid Review

Commenced Completed Outcome
07/11/2014 18/12/2014 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
10/04/2015  06/10/2015 Reimbursement Not Recommended

The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with relapsed or refractory MCL has not been demonstrated. Therefore it is not recommended for reimbursement at the submitted price.

Summary

The HSE has approved reimbursement following confidential price negotiations.